Evidence map›Paper›PMID 37948005›Full record

ReviewNeurology and therapy2024

Paroxysmal Sympathetic Hyperactivity After Acquired Brain Injury: An Integrative Review of Diagnostic and Management Challenges.

Sui-Yi Xu, Qi Zhang, Chang-Xin Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. New insights and predictability from in vivo recordings of paroxysmal sympathetic hyperactivity in disorders of consciousness.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  4. Review
  5. Observational
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Paroxysmal Sympathetic Hyperactivity after Traumatic Brain Injury: Current Understanding and Therapeutic Options.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sui-Yi Xu *Department of Neurology, Headache Center, The First Hospital of Shanxi Medical University, Jiefangnan 85 Road, 030001, Taiyuan, Shanxi, People's Republic of China.
Qi Zhang *Department of Neurology, Headache Center, The First Hospital of Shanxi Medical University, Jiefangnan 85 Road, 030001, Taiyuan, Shanxi, People's Republic of China.
Chang-Xin LiDepartment of Neurology, Headache Center, The First Hospital of Shanxi Medical University, Jiefangnan 85 Road, 030001, Taiyuan, Shanxi, People's Republic of China. lichangxin0351@sina.com.ORCID http://orcid.org/0000-0001-8652-4283
Shanxi Medical University · CN

Funding

Doctoral Fund of the First Hospital of Shanxi Medical University BS03201631Doctoral Fund of the First Hospital of Shanxi Medical University SD2215Doctoral Fund of the First Hospital of Shanxi Medical University YB161706Shanxi Applied Basic Research Program 201801D221426Shanxi Applied Basic Research Program 20210302124404Shanxi Provincial Health and Family Planning Commission 2017033Shanxi Provincial Health and Family Planning Commission 2020080
6 · The paper itself

Abstract

Paroxysmal sympathetic hyperactivity (PSH) mainly occurs after acquired brain injury (ABI) and often presents with high fever, hypertension, tachycardia, tachypnea, sweating, and dystonia (increased muscle tone or spasticity). The pathophysiological mechanisms of PSH are not fully understood. Currently, there are several views: (1) disconnection theory, (2) excitatory/inhibitory ratio, (3) neuroendocrine function, and (4) neutrophil extracellular traps. Early diagnosis of PSH remains difficult, given the low specificity of its diagnostic tools and unclear pathogenesis. According to updated case analyses in recent years, PSH is now more commonly observed in patients with stroke, with tachycardia and hypertension as the main clinical manifestations, which is not fully consistent with previous data. To date, the PSH Assessment Measure tool is optimal for the early identification of PSH and stratification of symptom severity. Clinical strategies for the management of PSH are divided into three main points: (1) reduction of stimulation, (2) reduction of sympathetic excitatory afferents, and (3) inhibition of the effects of sympathetic hyperactivity on target organs. However, use of drugs and standards have not yet been harmonized. Further investigation on the relationship between PSH severity and long-term neurological prognosis in patients with ABI is required. This review aimed to determine the diagnostic and management challenges encountered in PSH after ABI.

Indexed as

Brain injuryClinical managementDiagnostic criteriaParoxysmal sympathetic hyperactivityRisk factors

Identifiers

PMID37948005
PMCPMC10787720
OpenAlexW4388573836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.